I previously posted the audio version of Futures in Biotech episode 50: More biotech stories. In this episode I joined host Marc Pelletier and George Farr, Justin Sanchez, and Dave Brodbeck for a discussion on recent big stories in bioscience. Topics included erasing memory, controlling neurons with light, the role of the new virus XMRV in prostate cancer and chronic fatigue syndrome, and prions as genetic elements in yeast.
For those of you who prefer watching the speakers, here is a video version of the same podcast, courtesy of Team ODTV.
Get the Flash Player to see this player.
//
Download video (149 MB .mp4) (Source: virology blog)

Original post by virology blog and software by Elliott Back

I joined host Marc Pelletier and George Farr, Justin Sanchez, and Dave Brodbeck for a discussion on recent big stories in bioscience. Topics included erasing memory, controlling neurons with light, the role of the new virus XMRV in prostate cancer and chronic fatigue syndrome, and prions as genetic elements in yeast.
Download Futures in Biotech 50 or subscribe to the podcast in iTunes. (Source: virology blog)

Original post by virology blog and software by Elliott Back

Xenotropic murine leukemia virus related virus (XMRV) has been implicated in prostate cancer and chronic fatigue syndrome (CFS). Because XMRV is a retrovirus, it has been suggested that it might be susceptible to some of the many drugs available for treatment of AIDS. Of ten licensed compounds evaluated for activity against XMRV, just one, AZT (azidothymidine), was found to inhibit viral replication.
Compounds used to treat HIV-1 infection fall into distinct classes: protease inhibitors (Ritonavir, Saquinavir, or Indinavir), nucleoside reverse transcriptase inhibitors (NRTI, AZT, 3TC, Tnofovir, D4T), non-nucleoside reverse transcriptase inhibitors (NNRTI, Efavirenz, Nevirapine), integrase inhibitors (118-D-24), and fusion inhibitors (Maraviroc). None of the HIV-1 protease inhibitors, NNRTI…

Original post by virology blog and software by Elliott Back